Resumo:
The implant failures present rate of 10% worldwide, causing losses of 20 billion dollars
per year. The impact of this reality is socioeconomic, as it also harms patients with physical
pain, psychological trauma and restricted mobility. Studies of surface modifications in titanium
implants have been investigated to reduce the incidence of bacteria on the surface of
biomaterials. Surface treatments coated with TiO2 nanotubes associated with antimicrobial
compounds are a possible solution to reduce the rate of failures caused by bacteria. The
objective of this work is to associate TiO2 nanotubes to two novel hybrid pyrazol-tetrazol
compounds, the compound 5-[1-(3-chlorophenyl)-3-methyl-1H-pyrazol-4-yl)]-1H-tetrazol
(JVS02 ) and 5-[1-(3,4-dichlorophenyl)-3-methyl-1H-pyrazol-4-yl)]-1H-tetrazol (JVS05), to
reduce bacteria on the surface of pure titanium biomaterials for implants. The material was
evaluated by scanning electron microscope (SEM), X-ray diffraction (XRD) and contact angle.
The compounds associated with TiO2 nanotubes were characterized by drug release test and the
biofilm test with Staphylococcus aureus bacteria of the HU25 strain. The results showed that
the anodization resulted in TiO2 nanotubes on the surface of the anodized material with
diameters of 50 nm, present in the rutile phase and the material became hydrophilic with an
average contact angle of 7.81°. The release test showed that compound JVS02 has an immediate
release and compound JVS05 has a gradual release with clear delimitation between phases. The
biofilm test showed that the JVS05 compound has greater action against the formation of
biofilm on the material's surface. With the results presented, we can conclude that there was
loading of both compounds studied in TiO2 nanotubes on titanium substrates and among these,
the compound 5-[1-(3,4-dichlorophenyl)-3-methyl-1H-pyrazol-4 -il)]-1H-tetrazol has more
adequate characteristics for a drug delivery system due to its release time and antimicrobial
action.
